

139. 'Mixed' β -Peptides: A Unique Helical Secondary Structure in Solution

Preliminary Communication

by Dieter Seebach*, Karl Gademann¹), Jürg V. Schreiber²), Jennifer L. Matthews³), Tobias Hintermann¹), and Bernhard Jaun

Laboratorium für Organische Chemie der Eidgenössischen Technischen Hochschule, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich

and Lukas Oberer, Ulrich Hommel, and Hans Widmer

Präklinische Forschung, Novartis Pharma AG, Research Core Technology Area, CH-4002 Basel

(13. VIII. 97)

β -Hexapeptides **1–5** and a β -dodecapeptide **6** with sequences containing two different types of β -amino acids (aliphatic proteinaceous side chains in the 2- or in the 3-position) have been prepared. CD (Fig. 1) and NMR measurements indicate that, with one exception, the secondary structures formed by these new β -peptides differ from those of isomers studied previously. Detailed NMR analysis of the β -hexapeptide **5** (with alternating β^2, β^3 -building blocks) and molecular-dynamics simulations have produced a minimum energy conformation (Fig. 2, b) which might be described as a novel irregular helix containing ten- and twelve-membered H-bonded rings. This demonstrates the great structural variability of β -peptides, since three different helical secondary structures have been discovered to date.



It has come as a surprise to specialists that short-chain β -peptides **A** ($n = 6, 7$) form distinct secondary structures in solution [1–6]. The β -peptides studied so far contain either β^2 -amino acids ($R^3 = H$ in **A**) [3], or β^3 -amino acids ($R^2 = H$ in **A**) [1] [2], or cyclic β -amino acids ($R^2 - R^3 = (CH_2)_n$, $n = 3$ or 4 , in **A**) [4] [5]. The most remarkable type of secondary structure is helical, and two entirely different helices have hitherto been identified: a 3_1 [1] [2] [4] and a $2,5_1$ [5] helix. The former contains 14-membered H-bonded rings (3_{14} helix), and has a dipole negative at the N- and positive at the C-terminus, the latter contains 12-membered rings ($2,5_{12}$ helix), with the dipole in the opposite direction. With substituents R^2 and R^3 in the (*Si*) half-space of the stereogenic centers in **A**, the 3_1 helix is left-handed (*M*) and the $2,5_1$ helix is right-handed (*P*) [6]. So far, only the 3_1 helix has been observed by NMR spectroscopy of β -peptides containing rotationally unrestricted β -amino-acid residues, and a distinct CD pattern (trough at 215 nm, peak at 200 nm) has been assigned to the (*M*) helix [2].

We have now synthesized 'mixed' β -peptides **1–6** containing both β^2 - and β^3 -amino acids (which were prepared and coupled by the methods described previously [1–3]). The


¹) Part of the projected Ph. D. theses of *K.G.* and *T.H.*, ETH-Zürich.

²) Part of the Master's thesis of *J.V.S.*, ETH-Zürich, 1997.


³) *Royal Society* (UK) Postdoctoral Research Fellow 1995–1996; *Swiss National Science Foundation* Fellowship Holder 1996–1997 (grant No. 21-40659.94).

**A**

- 1** PG = Boc, R = Bn
2 PG = R = H, trifluoroacetate



- 3** PG = Boc, R = Bn



- 4** $n = 1$, PG = Boc, R = Bn
5 $n = 1$, PG = R = H, hydrochloride
6 $n = 2$, PG = Boc, R = Bn

β -hexapeptides **1** and **2** are constructed from a triad of β^2 - and a triad of β^3 -amino-acid residues, while **3** results from fragment coupling of two $\beta^3, \beta^2, \beta^3$ -tripeptides. The third type (**4–6**) contains sequences of alternating β^2 - and β^3 -amino acids. To stay as close as possible to natural α -peptides and to the previously reported β -peptides, we chose the side chains of valine, alanine, and leucine, and the configuration of all stereogenic centers such that the now well-established (*M*) 3_1 helix could have been adopted by all β -peptides **1–6**.

We were stunned by the fact that only the deprotected β -hexapeptide **2** shows the familiar 215/200-nm CD pattern in MeOH solution, while all other new β -peptides **1** and **3–5**, including the β -dodecapeptide **6** show a new type of CD spectrum with a single peak at ca. 205 nm (Fig. 1), and a record intensity of molar ellipticity of $6.5 \cdot 10^5$ for **6**.

An NMR investigation of a $\text{C}_5\text{D}_5\text{N}$ solution of β -hexapeptide **5**, using TOCSY and ROESY experiments [7], resulted in full assignment of all resonances in the ^1H spectrum and in the determination of the sequence. Inspection of the ROESY cross-peaks showed




Fig. 1. CD Spectra of β -peptides 1–6 (ca. 0.2 mM in MeOH; mol. ellipticity in $\text{deg} \cdot \text{cm}^2 \cdot \text{dmol}^{-1}$). Only the deprotected hexapeptide 2 shows the characteristic pattern (blue curve in a) assigned to a β -peptide 3_1 helix [2]. All other samples (of 1 and 3–6) give rise to peaks at ca. 205 nm. a) CD Spectra of β -hexapeptides consisting of trimer blocks; red: 1, blue: 2; green: 3. b) CD Spectra of β -peptides with alternating β^2, β^3 sequences; red: 4; blue: 5; green: 6.




Fig. 2. Structures of the β -hexapeptide $H\text{-}\beta\text{-HVal-}\beta\text{-HAla-}\beta\text{-HLeu-}\beta\text{-HVal-OH}$ hydrochloride (**5**) as determined from NMR measurements (C_3D_5N solution). *a*) Side view of the structure obtained by NDE-restrained annealing MD simulation. *b*) Top view and top view of a low-energy conformer of **5** obtained by an unrestrained MD simulation *in vacuo* at 50 K, resulting from one of the structures shown in *a*. Figures were generated using the Raster3D program [11] [12].

significant NOEs between residues 2 and 4, and residues 4 and 6. This is in contrast to NOEs observed for a typical 3_1 helix, where additional i to $i + 3$ relations are found. Forty ROESY cross-peaks were ordered in three distance categories (strong $< 2.8 \text{ \AA}$, medium $< 3.5 \text{ \AA}$ and weak $< 4.5 \text{ \AA}$) which served as upper-bound distance restraints for standard annealing molecular-dynamics simulations using the X-PLOR package [8]. The calculation converged to a bundle of structures with a central ten-membered H-bonded turn shown in *Fig. 2, a*, while the H-bonding between residues 1 and 4, as well as 3 and 6 is very weak. Since the force field used in this calculation does not account for H-bonding interactions, we decided to perform an unrestrained 50-ps molecular-dynamics simulation using AMBER* (MacroModel) [9] [10]. A conformation taken from the NOE-restrained modeling was used as starting structure for a molecular-dynamics simulation at 50 K *in vacuo*. The ten lowest-energy conformations of the trajectory were each minimized in energy and all converged to a single conformer depicted in *Fig. 2, b*. This minimized structure is still consistent with the NMR-derived structural family, but, in addition to the central ten-membered turn, twelve-membered H-bonding rings are present in both the C- and N-terminal regions.

This structure might be considered as a very unusual kind of helix, consisting of a wide, a narrow, and another wide turn. The sense of helicity is right-handed (P), and the helix has a strongly reduced dipole, since its amide C=O bonds point alternately up and down the helix axis. From the top view in *Fig. 2, b*, it is evident that the hydrophobic valine and leucine side chains are in juxtaposition on one side of the structure. If the β -peptide were to adopt a 3_1 helical conformation, the alignment of substituents described above would not occur and, thus, may be the reason why a 3_1 helical structure is not observed in this case (a detailed discussion will be given in a forthcoming full paper).

The so far unknown NMR structure of the β -peptide **5** in MeOH solution will tell us whether the characteristic CD spectra shown in *Fig. 1* are actually indicative of the helical structure described herein. It will also be interesting to learn whether the 12/10/12 ring pattern in this structure is repetitive in longer-chain analogs of **5** (such as **6**). Furthermore, the strikingly high solubility of the protected β -hexa- and β -dodecapeptide **4** and **6** in organic solvents (such as AcOEt) and the fact that the dodecamer **6** moves much faster on a thin-layer chromatography plate than the hexamer **4** will hopefully be understood as more structural information about the 'mixed' β -peptides with alternating β^2, β^3 residues becomes available.

We are indebted to Dr. *Xavier Daura* for help during the preparation of this manuscript. We gratefully acknowledge the financial support of the *Royal Society*, UK (fellowship to *J.L.M.*) and the *Swiss National Science Foundation* (grant No. 21-40659.94). We thank *Novartis Pharma AG*, Basel, for continuing support of the work done in Zürich. Generous supply of amino acids by *Degussa AG*, Hanau, of trifluoroacetic acid by *Solvay Deutschland*, Hannover, and of THF by *BASF*, Ludwigshafen, is greatly appreciated.

REFERENCES

- [1] D. Seebach, M. Overhand, F. N. M. Kühnle, B. Martinoni, L. Oberer, U. Hommel, H. Widmer, *Helv. Chim. Acta* **1996**, *79*, 913.
- [2] D. Seebach, P. E. Ciceri, M. Overhand, B. Jaun, D. Rigo, L. Oberer, U. Hommel, R. Amstutz, H. Widmer, *Helv. Chim. Acta* **1996**, *79*, 2043.
- [3] T. Hintermann, D. Seebach, *Synlett* **1997**, 437.

- [4] D. H. Apella, L. A. Christianson, I. L. Karle, D. R. Powell, S. H. Gellman, *J. Am. Chem. Soc.* **1996**, *118*, 13071.
- [5] D. H. Apella, L. A. Christianson, D. A. Klein, D. R. Powell, S. Huang, J. J. Barchi, S. H. Gellmann, *Nature (London)* **1997**, *387*, 381.
- [6] D. Seebach, J. L. Matthews, *Chem. Commun.* **1997**, Feature Article, to appear in November issue.
- [7] A. A. Bothner-By, R. L. Stephens, J. M. Lee, C. D. Warren, J. W. Jeanloz, *J. Am. Chem. Soc.* **1984**, *106*, 811; J. K. M. Sanders, B. K. Hunter, 'Modern NMR Spectroscopy, A Guide For Chemists', Oxford University Press, Oxford, 1993.
- [8] A. T. Brünger, in 'X-PLOR Manual V3.0', Yale University, New Haven, 1992.
- [9] D. Q. McDonald, W. C. Still, *Tetrahedron Lett.* **1992**, *33*, 7743.
- [10] F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, W. C. Still, *J. Comput. Chem.* **1990**, *11*, 440.
- [11] E. A. Merrit, M. E. P. Murphy, *J. Appl. Crystallogr.* **1994**, *24*, 946.
- [12] D. J. Bacon, W. F. A. Anderson, *J. Mol. Graphics* **1988**, *6*, 219.